Fig. 4From: The pharmacokinetics and pharmacodynamics of danirixin (GSK1325756) − a selective CXCR2 antagonist − in healthy adult subjectsPlot of individual subject danirixin blood dose-normalized AUC (A) and Cmax (B) versus dose for cohorts 1, 2, and 5 in Study 1 (FTIH). The geometric means (with 90 % confidence intervals) are also shownBack to article page